pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
645
stories
15d
Double shot of Vistagen’s anxiety nasal spray can’t beat placebo in ph. 2 trial
fiercebiotech
15d
FDA approves Moderna flu vaccine after spat with past agency leaders
endpoints
15d
FDA approves Moderna’s mRNA flu vaccine, the first to use the technology
stat
15d
Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expenses
endpoints
15d
Recon: FDA approves first drug for type 1 narcolepsy, mRNA flu vaccine; No merger talks between AstraZeneca-BMS
raps
15d
FDA approves Takeda's orexin drug for narcolepsy
endpoints
15d
STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
stat
16d
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms
fda press
16d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
16d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
16d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
16d
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
16d
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
16d
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
16d
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
biospace
16d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
16d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
16d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
17d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
17d
STAT+: Are AI scribes medical devices? U.K. regulator weighs in
stat
17d
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
stat
17d
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
fiercebiotech
17d
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
stat
17d
Vertex unfazed by competitive IgAN space as FDA verdict looms
biospace
17d
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
fiercebiotech
17d
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
fiercebiotech
← prev
page 6 of 22
next →
